Rahul Aggarwal, MD

Developmental therapeutics specialist
Genitourinary oncologist

Dr. Rahul Aggarwal is a genitourinary cancer specialist at the UCSF Helen Diller Family Comprehensive Cancer Center. He also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men with prostate cancer who are receiving androgen deprivation therapy, also known as hormone therapy. In addition, as a member of the Developmental Therapeutics Genitourinary Cancer Program, Aggarwal enrolls patients with advanced solid tumor malignancies into early phase clinical trials of novel targeted treatments. His research is focused on developing novel hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer. Aggarwal is also interested in developing novel molecular imaging techniques as a prognostic and predictive biomarker of tumor response among patients with advanced solid tumors.

Aggarwal earned a medical degree from Northwestern University Feinberg School of Medicine. Subsequently, he completed an internship and residency in internal medicine followed by a clinical fellowship in hematology/oncology at UCSF. Aggarwal was also a research fellow in developmental therapeutics at Genentech, Inc. in South San Francisco. He is a member of the American Society of Clinical Oncology (ASCO) and recipient of the ASCO/Conquer Cancer Foundation Young Investigator Award. Aggarwal is an assistant clinical professor of medicine at UCSF.

Clinics

Genitourinary Medical Oncology
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 476-4616
Fax: (415) 353-7107

Hours: Monday to Friday
8 a.m. – 5 p.m.

STAND Clinic
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 885-7795
Fax: (415) 353-7093

Board Certification

Internal Medicine, American Board of Internal Medicine

Academic Title

Assistant Professor

More about Rahul Aggarwal

Education

Northwestern University Feinberg School of Medicine 2006

Residencies

UCSF Medical Center, Internal Medicine 2009

Fellowships

UCSF Medical Center, Hematology/Oncology 2013

Selected Research and Publications

  1. Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer. 2017 Sep 19; 5(1):75.
  2. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107.
  3. Dhawan MS, Bartelink IH, Aggarwal R, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser MM, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential toxicity in patients with and without DNA repair mutations: Phase I Study of Carboplatin and Talazoparib in advanced solid tumors. Clin Cancer Res. 2017 Aug 08.
  4. Aggarwal RR, Feng FY, Small EJ. Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications. Oncology (Williston Park). 2017 06 15; 31(6):467-74.
  5. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 Sep; 15(9):1221-1229.
  6. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Jun 03.
  7. Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, Small EJ, Link TM. CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. J Vasc Interv Radiol. 2017 Aug; 28(8):1073-1081.e1.
  8. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg M, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 May 18.
  9. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 Sep; 7(9):999-1005.
  10. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Apr 10; 35(11):1231-1239.
  11. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 Apr; 35(4):149.e7-149.e13.
  12. Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ. Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience. Mol Imaging. 2017 Jan-Dec; 16:1536012117723256.
  13. Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans MJ. A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Mol Imaging Biol. 2016 Dec; 18(6):946-951.
  14. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017 Jan; 58(1):81-84.
  15. Hope TA, Aggarwal RR, Westphalen AC, Cooperberg MR, Greene KL. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncol. 2016 Nov; 12(21):2393-2396.
  16. Aggarwal R. Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure? Eur Urol. 2016 Sep; 70(3):445-6.
  17. Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R. Approaches to minimize castration in the treatment of advanced prostate cancer. Urol Oncol. 2016 Aug; 34(8):368-74.
  18. Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 May; 27(5):947-52.
  19. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9.
  20. Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ. Somatostatin imaging of neuroendocrine-differentiated prostate cancer. Clin Nucl Med. 2015 Jun; 40(6):540-1.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.